David P Ellent MD
David P Ellent MD
MD, Internal Medicine and Medical Oncology (ABIM)
Education: Fellowship – University of Texas M.D. Anderson Cancer Clinic Heavily involved in drug research and development.
Publications: Cyclooxygenase-2 Derived Prostaglandin E2 Protects Mouse Embryonic Stem Cells from Apoptosis(p 1096-1103) Jun-Yang Liou, David P. Ellent, Jennifer Goldsby,Bor-Sheng Ko, Nena Matijevic,Jaou-Chen Huang, Kenneth.K. Wu DOI: 10.1634/stemcells.2006-0505.
Gemtuzumab ozogamicin (Mylotarg) Prior to Allogeneic Hematopoietic Stem Cell Transplantation Increases the Risk of Hepatic Veno-occlusive Disease: American Society of Hematology (poster presentation) Blood. Stuart Goldberg, MD;David Ellent, MD; Dmitry Shtrambrand, MD; May Abdo-Matkiwsky, DO; Stephanie Hamarman, MD; Jack W Hsu, MD; Scott D Rowely, MD; and Andrew L Pecora, MD.
Autologous hematopoietic stem cell transplantation (HSCT) for the treatment of HIV-infected patients on HAART with non-Hodgkin’s lymphoma: D.P. Ellent, S.D. Rowely, S.L. Goldberg. A.L. Pecora, J.W. Hsu, D.S. Siegel; University of Medicine and Dentistry of New Jersey, Newark, NJ; Hackensack University Medical Center, Hackensack NJ Proc Am Soc Clin Oncol 22: page 600, 2003 (abstr 2414)
Research and Presentations:
City wide conferences within Houston Texas 2002 ASH Annual Meeting- poster presentation- Gemtuzumab ozogamicin (Mylotarg) Prior to Allogeneic Hematopoietic Stem Cell Transplantation increases the risk of Hepatic Veno-occlusive Disease,2003 ASCO Annual Meeting – poster presentation- Autologus hematopoietic stem cell transplantation (HSCT) for the treatment of HIV- infected patients on HAART with non-Hodgkin’s Lymphonam in HIV positive patients and extensive investigation of venoclusive disease after administration of Mylotarg Research investigation pathways of differentiation of stem cells.